Ironwood Pharmaceuticals, Inc.
IRWD
$4.31
$0.235.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 32.62% | 158.87% | -47.31% | 33.26% | -9.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.62% | 158.87% | -47.31% | 33.26% | -9.70% |
| Cost of Revenue | -4.07% | -20.02% | -13.89% | -24.67% | -23.08% |
| Gross Profit | 46.48% | 516.77% | -60.33% | 61.24% | -3.35% |
| SG&A Expenses | -32.64% | -50.40% | -42.03% | -39.33% | -54.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.02% | -34.28% | -29.79% | -32.70% | -40.36% |
| Operating Income | 75.96% | 787.58% | -79.05% | 202.84% | 66.66% |
| Income Before Tax | 94.94% | 279.68% | -98.10% | 291.62% | 100.37% |
| Income Tax Expenses | 57.77% | 2,090.22% | -87.44% | 103.60% | -27.93% |
| Earnings from Continuing Operations | 117.34% | 209.06% | -200.89% | 999.29% | 2,844.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 117.34% | 209.06% | -200.89% | 999.29% | 2,844.07% |
| EBIT | 75.96% | 787.58% | -79.05% | 202.84% | 66.66% |
| EBITDA | 75.16% | 824.69% | -77.96% | 198.78% | 65.29% |
| EPS Basic | 113.85% | 207.45% | -199.29% | 983.77% | 2,801.85% |
| Normalized Basic EPS | 93.04% | 462.06% | -99.15% | 297.94% | 76.43% |
| EPS Diluted | 125.62% | 203.36% | -270.92% | 1,047.00% | 1,474.00% |
| Normalized Diluted EPS | 107.53% | 454.94% | -99.15% | 264.16% | 61.36% |
| Average Basic Shares Outstanding | 1.66% | 1.54% | 1.59% | 1.57% | 1.70% |
| Average Diluted Shares Outstanding | -5.46% | 3.55% | 1.26% | 10.94% | 11.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |